These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24964745)

  • 1. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort.
    Sciascia S; Cuadrado MJ; Sanna G; Murru V; Roccatello D; Khamashta MA; Bertolaccini ML
    Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1915-20. PubMed ID: 24964745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?
    Uludağ Ö; Çinar S; McDonnell T; Çene E; Yalçinkaya Y; Gül A; Inanç M; Artim Esen B
    Turk J Med Sci; 2023; 53(5):1067-1074. PubMed ID: 38813003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GAPSS: the Global Anti-Phospholipid Syndrome Score.
    Sciascia S; Sanna G; Murru V; Roccatello D; Khamashta MA; Bertolaccini ML
    Rheumatology (Oxford); 2013 Aug; 52(8):1397-403. PubMed ID: 23315788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina.
    Garcia L; Velloso MS; Martire MV; Savy F; Arizpe F; Garcia N; Testi A; Pena C; Costi AC; Isnardi C; Capelusnik D; Mazza S; Curi YS; Collado V; Rodriguez MF; Scarafia S; Pisoni C; de la Torre M; Seewald A; Riva ME; Garcia M
    Lupus; 2020 Dec; 29(14):1866-1872. PubMed ID: 33028177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
    Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
    Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global Antiphospholipid Syndrome Score (GAPSS) in Patients with Systemic Lupus Erythematosus.
    Cheldieva FA; Reshetnyak TM; Shumilova AA; Nurbaeva KS; Cherkasova MV; Lila AM; Nasonov EL
    Dokl Biochem Biophys; 2023 Aug; 511(1):227-234. PubMed ID: 37833610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study.
    Zuily S; de Laat B; Mohamed S; Kelchtermans H; Shums Z; Albesa R; Norman GL; Lamboux-Matthieu C; Rat AC; Ninet J; Magy-Bertrand N; Pasquali JL; Lambert M; Lorcerie B; Kaminsky P; Guillemin F; Regnault V; Wahl D;
    Rheumatology (Oxford); 2015 Nov; 54(11):2071-5. PubMed ID: 26163690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The global anti-phospholipid syndrome score in primary APS.
    Sciascia S; Sanna G; Murru V; Roccatello D; Khamashta MA; Bertolaccini ML
    Rheumatology (Oxford); 2015 Jan; 54(1):134-8. PubMed ID: 25122726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martínez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Rueda M; Aguirre C
    Lupus; 2004; 13(12):927-33. PubMed ID: 15645748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
    Chen J; Sun S; Yan Q; Bao C; Fu Q
    Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent validation of the adjusted GAPSS: Role of thrombotic risk assessment in the real-life setting.
    Fernandez Mosteirin N; Saez Comet L; Salvador Osuna C; Calvo Villas JM; Velilla Marco J
    Lupus; 2017 Oct; 26(12):1328-1332. PubMed ID: 28387637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study.
    Stojanovich L; Markovic O; Marisavljevic D; Elezovic I; Ilijevski N; Stanisavljevic N
    Lupus; 2012 Mar; 21(3):338-45. PubMed ID: 21993381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martinez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Garmendia M; Gabriel Erdozain J; Villar I; Aguirre C
    Lupus; 2007; 16(10):810-6. PubMed ID: 17895304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study.
    Nascimento IS; Radin M; Gândara APR; Sciascia S; de Andrade DCO
    Lupus; 2020 Jun; 29(7):676-685. PubMed ID: 32279584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.
    Ho KT; Ahn CW; Alarcón GS; Baethge BA; Tan FK; Roseman J; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Calvo-Alén J; Reveille JD
    Rheumatology (Oxford); 2005 Oct; 44(10):1303-7. PubMed ID: 16030085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study.
    Berube C; Mitchell L; Silverman E; David M; Saint Cyr C; Laxer R; Adams M; Vegh P; Andrew M
    Pediatr Res; 1998 Sep; 44(3):351-6. PubMed ID: 9727712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
    Somers E; Magder LS; Petri M
    J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid antibody tests: spreading the net.
    Bertolaccini ML; Gomez S; Pareja JF; Theodoridou A; Sanna G; Hughes GR; Khamashta MA
    Ann Rheum Dis; 2005 Nov; 64(11):1639-43. PubMed ID: 15817655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.